Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: My thoughts....

I believe the question has been asked of and answered by PTSC IR regarding whether PTSC can continue with its share buyback program (I believe Hawk answered NO).  However, based on Hawk telling someone that PTSC had until the 14th of Jan to file the 10-Q, when it's pretty clear it's the 9th,  it's hard to put much faith in Hawk's answers about much anyway.

That being said, IF PTSC HAS been buying  back shares, it sure would be nice to see in the subsequent events section of the upcoming 10-Q that they have purchased say $30M worth of stock since 11/30.  Considering they have announced that their buyback plan would be predicated on not less than 10% of the future license fees, we could assume that the settlements and licenses signed since 11/30 could be worth a maximum of $300M sicce the minimum they would spend on share buybacks is 10% of the fees.  They could also release info about the non-settlement licenses and their values, and thus we could back into the settlement figures in a way.

Not a bad way to give us a window into the settlement figures without breaching the NDA.

Share
New Message
Please login to post a reply